Clinical Research Directory
Browse clinical research sites, groups, and studies.
Pharmacokinetic Study of Tranexamic Acid
Sponsor: Zhejiang Cancer Hospital
Summary
Tranexamic acid is an effective anti fibrinolytic drug. Clinical studies have found that intravenous injection of tranexamic acid is more effective in reducing blood loss and transfusion in patients with advanced ovarian cancer, without increasing the risk of postoperative complications. Different surgeries and administration routes have an impact on the pharmacokinetics and pharmacodynamics of TXA. At present, there is little data on the pharmacokinetics of intramuscular injection of TXA, and almost all of the data comes from males. For ovarian cancer patients, there are currently no reports on the pharmacokinetics of TXA through different routes of administration, such as intramuscular and intravenous administration. Therefore, the investigators chose ovarian cancer patients and administered it through different routes of intravenous and intramuscular injection.
Official title: Pharmacokinetic Study and Clinical Efficacy Observation of Different Routes of Tranexamic Acid Infusion in Advanced Ovarian Cancer Cell Reduction Surgery
Key Details
Gender
FEMALE
Age Range
20 Years - 64 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2024-11-20
Completion Date
2025-08-31
Last Updated
2024-12-11
Healthy Volunteers
No
Conditions
Interventions
Tranexamic acid Intravenous Infusion
A slow intravenous infusion of 1g TXA was administered at a rate of about 1ml/min.
TXA intramuscular injection
5ml intramuscular injections of TXA with twice, each injection time no more than 30 seconds, the injection site was selected as triangle
Locations (1)
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China